/ /

Michelle Dalton, ELS
Novel treatment options for IOP involve range of independent factors
When exploring novel treatment options for the management of IOP, clinicians should consider a number of independent factors ranging from beneficial behaviors to body position.
Resistance to fluoroquinolones impacts retina cases
Antibiotic resistance against fluoroquinolones is increasing, and that may adversely impact patients with retinal disorders. The introduction of intravitreal injections (IVT) to treat retinal diseases has increased from about 1 million in 2007 to an expected 6 million in 2016 (up from only 4,000 in 2001).
Infections with EK procedures rising
Descemet’s stripping automated endothelial keratoplasty (DSAEK) appears to have a higher risk of postoperative fungal infections (predominantly Candida) when compared to penetrating keratoplasty (PK).
Real-world outcomes with aflibercept better in treatment-naïve patients
After 12 months of treatment with intravitreal aflibercept injections, both treatment-naïve and pre-treated patients demonstrated visual acuity gains. Visual acuity improvement was higher in treatment-naïve patients.
Novel glaucoma drug lowers IOP by unique combination of mechanisms
In a study of normal volunteers, once-daily dosing of netarsudil mesylate ophthalmic solution 0.02% lowered IOP relative to baseline by increasing outflow facility and decreasing episcleral venous pressure.
Inhibition of PlGF shows additional features compared to VEGF inhibition
Inhibition of PlGF shows additional features compared to VEGF inhibition
Anti-vascular endothelial growth factor (VEGF) remains the gold standard therapy for diabetic retinopathy, but “when treating diabetic macular edema (DME), “about half of the patients treated with VEGF inhibitors do not respond to therapy,” said Tine Van Bergen, PhD, a scientist with ThromboGenics, Leuven, Belgium.
Managing conjunctival pigmented lesions
Knowing how to recognize and manage the various forms of conjunctival pigmented lesions can literally mean the difference between life and death in some cases.
FDA approves tocilizumab, first therapy for GCA
FDA approves tocilizumab, first therapy for GCA
The FDA recently granted regulatory approval for tocilizumab (Actemra, Genentech), the first approved therapy for the treatment of adults with giant cell arteritis.
Pros and cons of compounded pharmaceuticals
Compounded pharmaceuticals have been used for decades, but does that mean they are reliable and safe? “Absolutely,” asserted Dante Pieramici, MD. “The literature disagrees,” said Julia Haller, MD.
Is DSAEK still the gold standard over DMEK for endothelial disease?
Multiple advantages of DSAEK include successful outcomes, less risk of graft tears, and alternative options for complex patients with comorbidities. Overall, the procedure offers an aspect of simplicity in that it also has less restrictions for donor age criteria compared with DMEK.

Poll

View Results